Company
Headquarters: York, United Kingdom
Employees: 164
CEO: Mr. Chris Henry Francis Yates
£16.1 Million
GBP as of Jan. 1, 2026
US$21.6 Million
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $222.61 B |
| Danaher | $164.98 B |
| Siemens Healthineers AG | $57.84 B |
| IDEXX Laboratories, Inc. | $53.62 B |
| Lonza Group Ltd | $47.58 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Abingdon Health Plc develops, manufactures, and distributes diagnostic devices worldwide. It offers AbC-19 Rapid Test, a COVID-19 IgG rapid antibody test; nucleic acid lateral flow immunoassays; Seralite, a rapid lateral flow test for the quantitative measurement of kappa and lambda immunoglobulin free light chains in serum; and AppDx, a customizable image capturing technology that transforms a smartphone into a self-sufficient and standalone lateral-flow reader. The company also provides lateral flow development and manufacturing services. Additionally, it provides consultancy services to businesses in the healthcare technology sector. The company has a collaboration and co-marketing agreement with Abcam plc. Abingdon Health Plc was incorporated in 2008 and is headquartered in York, the United Kingdom.
| Last Financial Reports Date | June 30, 2023 |
| Revenue TTM | £5.3 M |
| EBITDA | £-1,943,000 |
| Gross Profit TTM | £2.1 M |
| Profit Margin | -41.82% |
| Operating Margin | -60.75% |
| Quarterly Revenue Growth | 116.90% |
Abingdon Health plc has the following listings and related stock indices.
Stock: LSE: ABDX wb_incandescent